Medidur + Lucentis trial underway
A pilot study evaluating the safety and efficacy of Medidur FA (fluocinolone acetonide; Alimera) with Lucentis (ranibizumab; Novartis) against exudative age-related macular degeneration (wet AMD) has begun patient enrolment.
A pilot study evaluating the safety and efficacy of Medidur FA (fluocinolone acetonide; Alimera) with Lucentis (ranibizumab; Novartis) against exudative age-related macular degeneration (wet AMD) has begun patient enrolment.
Medidur FA is an intravitreal implant, currently in Phase III testing for diabetic macular oedema (DME), which delivers fluocinolone acetonide to the retina for up to three years.
The pilot study will evaluate the impact of Medidur FA on visual acuity and retinal thickness in patients who have been treated with Lucentis for a minimum of six months. Two doses of Medidur FA will be compared: 0.2 and 0.5 µg/day. The number of further Lucentis injections required after Medidur FA treatment begins will also be assessed.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
